Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Martha Hernandez‐Illas"'
Autor:
Jonathan A. Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey, Tami Crumley, Josee Cote, Julie Luk, Jeffrey R. Sachs, Kathryn Rutkowski, Harriet Park, Robert Schwab, William Joseph Howitt, Juan Carlos Rondon, Martha Hernandez-Illas, Terry O'Reilly, William Smith, Jakub Simon, Cathy Hardalo, Xuemei Zhao, Richard Wnek, Alethea Cope, Eseng Lai, Paula Annunziato, Dalya Guris, S. Aubrey Stoch
Publikováno v:
EBioMedicine, Vol 82, Iss , Pp 104138- (2022)
Summary: Background: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine can
Externí odkaz:
https://doaj.org/article/a44da410c7ec4f96838eaf6361e76d18
Autor:
Tong Lin, Martha Hernandez‐Illas, Andres Rey, Jack Jenkins, Reddy Chandula, Jeffrey A. Silverman, Mi Rim Choi
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 870-879 (2021)
L‐asparaginase has been an important component of acute lymphoblastic leukemia (ALL) therapy for over 40 years, and is standard therapy during ALL induction and consolidation treatment. L‐asparaginases are immunogenic and can induce hypersensitiv
Externí odkaz:
https://doaj.org/article/cea269d53d62419a8ed16d439badb8aa
Autor:
Shweta, Urva, Tamer, Coskun, Mei Teng, Loh, Yu, Du, Melissa K, Thomas, Sirel, Gurbuz, Axel, Haupt, Charles T, Benson, Martha, Hernandez-Illas, David A, D'Alessio, Zvonko, Milicevic
Publikováno v:
The Lancet. 400:1869-1881
Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic po
Autor:
Michael J. Koren, Patrick Maurice Moriarty, Seth J. Baum, Joel Neutel, Martha Hernandez-Illas, Howard S. Weintraub, Monica Florio, Helina Kassahun, Stacey Melquist, Tracy Varrieur, Saptarsi M. Haldar, Winnie Sohn, Huei Wang, Mary Elliott-Davey, Brooke M. Rock, Tao Pei, Oliver Homann, Jennifer Hellawell, Gerald F. Watts
Publikováno v:
Nature Medicine. 28:96-103
Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development of olpasiran, a firs
Autor:
Peter Trainer, Christine Ferrara-Cook, Alejandro Ayala, Rosa Luo, Stephanie Miller, Yang Wang, Martha Hernandez-Illas, Struthers R. Scott, Stephen Betz, Alan Krasner
Publikováno v:
Endocrine Abstracts.
Autor:
Mi Rim Choi, Tong Lin, Jack Jenkins, Reddy Chandula, Andres Rey, Martha Hernandez-Illas, Jeffrey A. Silverman
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 3, Pp 870-879 (2021)
Clinical and Translational Science, Vol 14, Iss 3, Pp 870-879 (2021)
L‐asparaginase has been an important component of acute lymphoblastic leukemia (ALL) therapy for over 40 years, and is standard therapy during ALL induction and consolidation treatment. L‐asparaginases are immunogenic and can induce hypersensitiv
Autor:
Stephen Betz, Christine Ferrara-Cook, Martha Hernandez-Illas, Rosa Luo, Ajay Madan, Stephanie Miller, Scott Struthers, Peter Trainer, Yang Wang, Alan Krasner
Publikováno v:
Journal of the Endocrine Society. 6:A83-A83
CRN04894 is a potent orally bioavailable MC2R (adrenal cortex specific ACTH receptor) antagonist (Kb=0.34 nM) that is >1000-fold selective for MC2R over other melanocortin receptor subtypes. In rats receiving continuous administration of ACTH via sub
Autor:
Huei Wang, Gerald F. Watts, Helina Kassahun, Patrick M. Moriarty, Joel M. Neutel, Mary Elliott-Davey, Michael J. Koren, Jennifer Hellawell, Winnie Sohn, Howard Weintraub, Seth J. Baum, Tracy Varrieur, Martha Hernandez-Illas
Publikováno v:
Circulation. 142
Introduction: Mendelian and epidemiological randomization studies have identified lipoprotein(a) [Lp(a)] as a risk factor for myocardial infarction and other atherosclerotic events. There are currently no approved medicines that selectively target Lp
Autor:
Martha Hernandez-Illas, Yukitoshi Narukawa, Shiro Miyazaki, Takayuki Katsube, Toshihiro Wajima
Publikováno v:
European Journal of Clinical Pharmacology. 74:931-938
Cefiderocol, a siderophore cephalosporin, will be used concomitantly with other medications for treatment of bacterial infections. In vitro studies demonstrated inhibition potential of cefiderocol on organic anion transporter (OAT) 1, OAT3, organic c
Autor:
Roland Schuler, Michael Rotte, Yan-Ling He, Peter Gergely, Pascal Espie, Laurence Colin, Anita Auger, Heidi Mergentaler, Martha Hernandez‐Illas, James S. Rush, Jacinda Ristov, Julie Milojevic, Denise Sickert, Cyrielle Dupuy, Alexandre Avrameas, Edwige Chokote, Phillip Koo, Aurelie Verles, Andrea Groenewegen, Charles S. Tomek
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsReferences. 20(2)
Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppressive agent. We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the safety, tolerability